In stratified survival analysis, Bmi-1 expression could stratify the outcome of patients in hige-grade (grade 2/3) serous carcinoma (P = 0.045), mucinous carcinoma (P = 0.001) and undifferentiated carcinoma (P = 0.001) subgroups. This evidence concerns the gene BMI1 and serous adenocarcinoma.